BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//KO
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA 일정 캘린더
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-2@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:승인 결정일(PDUFA): Aquestive Therapeutics\, Inc. (AQST) — A
 naphylm (dibutepinephrine)
DESCRIPTION:중증 알레르기·아나필락시스 설하 필름 Anaphylm 
 신약 재신청(Class 2) FDA PDUFA 목표 심사일.\n출처: https://www
 .sec.gov/Archives/edgar/data/1398733/000139873326000079/jefferiesglobalhea
 lthcar.htm\nhttps://catalystbrief.girapphe.com/e/2?lang=ko\n투자 조언
 이 아닙니다. 일정은 변경될 수 있습니다.
URL:https://catalystbrief.girapphe.com/e/2?lang=ko
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
